Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti-PD-1 and anti-PD-L1, have become established treatment (tx) options in various solid tumors. However, there is a paucity of data on checkpoint inhibitors in NET. In a phase I trial of PDR001 (mAb checkpoint inhibitor targeting PD-1) conducted in patients (pts) with multiple solid tumor types, a pt with histologically confirmed metastatic atypical pulmonary carcinoid demonstrated a RECIST-based tumor response and clinical benefit.
Aim(s): This study will evaluate the antitumor activity, safety, and tolerability of single-agent PDR001 in pts with progressive, non-functional NET.
Materials and methods: Pts with non-functional unresectable advanced well-differentiated grade 1/2 NET of GI, pancreatic or thoracic origin who progressed on or after prior available tx will be included. Overall response rate is the primary outcome and duration of response and safety are the key secondary outcomes, respectively.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: James C Yao
Yao J C
, Fazio N
, Pavel M
, Strosberg J
, Bergsland E
, Ruszniewski P
, Voi M
, Wu C
, Degtyarev E
, Aimone P
, Singh S
To read results and conclusion, please login ...
Further abstracts you may be interested in